Osteoporosis

Wyeth selects drug targets in osteoporosis collaboration with Belgium company

Published in Women's Health Weekly, January 27th, 2005

Galapagos Genomics, located in Mechelen, Belgium, announced that it has reached a research milestone in its osteoporosis discovery program with Wyeth Pharmaceuticals, the pharmaceutical division of Wyeth (WYE).

Within the program, which was initiated November, 2003, Galapagos has used its osteoporosis disease expertise in combination with its SilenceSelect adenoviral siRNA platform to discover and validate novel drug targets that may affect bone remodeling.

Wyeth has now selected a set of these targets for internal development, triggering a financial milestone for Galapagos. As these targets are progressed by Wyeth, Galapagos has rights to additional...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2005-01-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry